Immune Checkpoint Inhibitor-Associated Myocarditis
Specificity of definition of ICI-related myocarditis improved after minor change
A modified version of the International Cardio-Oncology Society definition of immune checkpoint inhibitor-associated myocarditis may improve its predictive value, researchers reported.
Timely intervention critical for major cardiac events after immune checkpoint therapy
CHICAGO — Patients and prescribers should be more aware of the potential for major adverse cardiac events after immune checkpoint inhibitor-based therapy, according to retrospective study results presented at ASCO Annual Meeting.
Myocarditis from immune checkpoint inhibitors linked with life-threatening arrhythmias
According to a new study, immune checkpoint inhibitor-induced myocarditis is highly associated with arrhythmias and ECG findings including new conduction blocks, decreased voltage and repolarization abnormalities.
Patients with checkpoint-induced myositis, overlap syndrome face worse outcomes
Myositis due to immune checkpoint therapy is rare yet severe, with more than half of patients developing overlapping myasthenia gravis and/or myocarditis, leading to extended hospitalizations and respiratory failure, researchers noted.
Global longitudinal strain predicts CV risk in immune checkpoint inhibitor-related myocarditis
Patients with myocarditis related to immune checkpoint inhibitors and either a preserved or reduced ejection fraction had a reduced global longitudinal strain, according to a study published in the Journal of the American College of Cardiology.